| melanoma
Imlygic vs Tecentriq
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Imlygic vs Tecentriq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecentriq has a higher rate of injection site reactions vs Imlygic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecentriq but not Imlygic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Imlygic
Tecentriq
At A Glance
Intralesional injection
Every 2-3 weeks
Oncolytic viral therapy
IV infusion
Every 2-4 weeks
PD-L1 antagonist
Indications
- Melanoma
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Liver carcinoma
- Melanoma
- Alveolar Soft Part Sarcoma
Dosing
Melanoma Initial dose up to 4 mL at 1 million PFU/mL intralesionally; second dose 3 weeks later up to 4 mL at 100 million PFU/mL; all subsequent doses every 2 weeks up to 4 mL at 100 million PFU/mL.
Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.
Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.
Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.
Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.
Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.
Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.
Contraindications
- Immunocompromised patients, including those with primary or acquired immunodeficiency, leukemia, lymphoma, AIDS or other clinical manifestations of HIV infection, or on immunosuppressive therapy
- Pregnant patients
—
Adverse Reactions
Most common (>=25%) Fatigue, chills, pyrexia, nausea, influenza-like illness, injection site pain
Serious Cellulitis (most common grade 3+ reaction), herpetic infection, injection site complications
Postmarketing Disseminated herpetic infections, including serious and fatal cases in immunocompromised patients
Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).
Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.
Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.
Pharmacology
Oncolytic viral therapy; genetically modified live attenuated HSV-1 that replicates within tumors causing lysis and release of tumor-derived antigens, and produces GM-CSF to promote an antitumor immune response; exact mechanism of action is unknown.
Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Imlygic
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
Tecentriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Imlygic
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tecentriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Imlygic
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tecentriq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tecentriq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ImlygicView full Imlygic profile
TecentriqView full Tecentriq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.